Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Deborah M StephensYing HuangAmy S RuppertJanek S WalkerDaniel CanfieldCasey B CempreQiang FuSharyn D BakerBoyu HuHarsh ShahRenee VadeboncoeurKerry A RogersSeema A BhatSamantha M JaglowskiHank LockmanRosa LapalombellaJohn C ByrdJennifer A WoyachPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The selinexor and ibrutinib combination has demonstrated tolerability in patients with relapsed/refractory CLL/NHL. Responses were durable. Notable responses were seen in patients with CLL with minimal prior therapy. Future study of this combination will focus on efforts to deepen remissions in patients with CLL receiving ibrutinib therapy.